Our Vision & Mission
Vision: We harness the power of nature to make the world more sustainable.
Mission: We make BioSolutions that improve our customers’ products and manufacturing processes while protecting the environment.
Our Heritage
From the Institute for Protein Design to industry scale
Arzeda was founded by David Baker (2024 Nobel Prize in Chemistry), Alexandre Zanghellini, and colleagues from the Institute for Protein Design at the University of Washington — one of the world's leading centers for computational biology. Together they set out to translate breakthrough science into products people could actually use and that have a positive impact in the world.
We have been a pioneer in computational protein design since 2008, when the field was still emerging. We were the first to computationally design enzymes from scratch. The first to use generative AI for commercial protein design long before it became a buzzword. The first to invest millions of dollars to build data systems specifically engineered to fulfill the promise of agentic AI protein design.
And you know where we were also first? Launching AI-designed enzyme products in the market, putting them in the hands of the customer and bridging the valley of death between algorithms and the real world. We are immensely proud of it. And we are only getting started!
Open Science
OpenFold & advancing the field
Arzeda co-founded OpenFold, a non-profit consortium developing open-source AI and software for protein structure prediction and design. We believe shared tools and transparent science lift the entire ecosystem — from academia to industry.
Our commitment to open science complements the proprietary programs we run with partners: we invest in public infrastructure so the field moves faster, while delivering differentiated outcomes for customers who need reliability at scale and new modes of performance.
Milestones
Key moments in our journey
- 2026
Strategic partnership with Mane to accelerate ViaLeaf™ global sales
- 2026
Second Arzeda product launched in a different industrial vertical
- 2025
$60M Series B2 financing; ViaLeaf™ expands production to a second site in the EU
- 2025
ViaLeaf™ sales exceed 5% of the global RebM market
- 2025
$15M NSF grant to develop foundational cell-free enzymatic bioconversion technology
- 2024
First Arzeda product launched — ViaLeaf™ Stevia (food ingredients vertical)
- 2023
$33M Series B1 financing
- 2021
Strategic alliance established with Unilever to transform home and personal-care products with AI protein design
- 2019
Strain engineering, fermentation, and downstream processing competencies established in-house
- 2019
Platform-wide LIMS deployed
- 2018
$15M Series A financing
- 2014
Multiple collaborations in sustainable chemicals and materials (INVISTA, Mitsubishi)
- 2012
Experimental lab set up at Arzeda to validate designs
- 2012
Team grows past 10 scientists
- 2011
First successful novel enzyme designed by Arzeda, tested in collaboration with DuPont-Pioneer (Agbiotech)
- 2010
Arzeda transitions to full cloud compute
- 2009
CRAY CX1, the company's first owned compute cluster, comes online — Arzeda is a pure software-development and computational-design company at this stage
- 2009
Arzeda begins operations